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Summary Paragraph 67 
A major goal of biomedicine is to understand the function of every gene in the human 68 
genome.1 Loss-of-function (LoF) mutations can disrupt both copies of a given gene in 69 
humans and phenotypic analysis of such ‘human knockouts’ can provide insight into gene 70 
function. To date, comprehensive analysis of genes knocked out in humans has been 71 
limited by the fact that LoF mutations are infrequent in the general population and so, 72 
observing an individual homozygous LoF for a given gene is exceedingly rare.2,3 73 
However, consanguineous unions are more likely to result in offspring who carry LoF 74 
mutations in a homozygous state. In Pakistan, consanguinity rates are notably high.4 75 
Here, in order to understand consequences of complete gene disruption in humans, we 76 
sequenced the protein-coding regions of 10,503 adult participants living in Pakistan, 77 
identified individuals carrying predicted LoF (pLoF) mutations in the homozygous state, 78 
and performed phenotypic analysis involving >200 traits. We enumerated 49,138 rare (<1 79 
% minor allele frequency) pLoF mutations. These pLoF mutations are predicted to knock 80 
out 1,317 genes in at least one participant. Homozygosity for pLoF mutations at PLAG27 81 
was associated with absent enzymatic activity of soluble lipoprotein-associated 82 
phospholipase A2; at CYP2F1, with higher plasma interleukin-8 concentrations; at 83 
TREH, with lower concentrations of apoB-containing lipoprotein subfractions; at either 84 
A3GALT2 or NRG4, with markedly reduced plasma insulin C-peptide concentrations; and 85 
at SLC9A3R1, with mediators of calcium and phosphate signaling. Finally, APOC3 is a 86 
gene which regulates metabolism of plasma triglyceride-rich lipoproteins and where 87 
heterozygous deficiency confers resistance to coronary heart disease.5,6 In Pakistan, we 88 
now observe APOC3 homozygous pLoF carriers; we recalled these knockout humans and 89 
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challenged with an oral fat load. Compared with wild-type family members, APOC3 90 
knockouts displayed marked blunting of the usual post-prandial rise in plasma 91 
triglycerides. Overall, these observations provide a roadmap for a ‘human knockout 92 
project’, a systematic effort to understand the phenotypic consequences of complete 93 
disruption of genes in humans.   94 
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Main Text 95 
 We studied adult participants in the Pakistan Risk of Myocardial Infarction Study 96 
(PROMIS) designed to understand the determinants of cardiometabolic diseases in South 97 
Asians.7 Consanguineous marriages have been common in this region of South Asia for 98 
many generations.8 In PROMIS, 39.0% of participants reported that their parents were 99 
cousins and 39.8% reported themselves being married to a cousin. An expectation from 100 
consanguinity is long regions of autozygosity, defined as homozygous loci identical by 101 
descent.9 Using genome-wide genotyping data available in 18,541 PROMIS participants, 102 
we quantified the length of runs of homozygosity, defined as homozygous segments at 103 
least 1.5 megabases long. We compared the lengths of runs of homozygosity among 104 
PROMIS participants with those seen in other populations from the International 105 
HapMap3 Project. Median length of genome-wide homozygosity among PROMIS 106 
participants was 6-7 times higher than participants of European (CEU, TSI) (P = 3.6 x 10-107 
37), East Asian (CHB, JPT, CHD) (P = 5.4 x 10-48) and African ancestries (YRI, MKK) 108 
(P = 1.3 x 10-40), respectively (Supplementary Figure 1).  109 
In order to identify individuals who are homozygous for predicted loss-of-110 
function (pLoF) mutations (i.e., nonsense, frameshift, or canonical splice-site mutations 111 
predicted to inactivate a gene), we performed whole exome sequencing in 10,503 112 
PROMIS participants (Table 1) with genetic ancestry similar to the overall cohort. 113 
Across all participants, 1,639,223 exonic and splice-site sequence variants in 19,026 114 
autosomal genes passed quality control metrics. Of these, 57,137 mutations across 14,345 115 
autosomal genes were annotated as pLoF.  116 
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To increase the probability that mutations annotated as pLoF by automated 117 
algorithms are bona fide, we removed nonsense and frameshift mutations occurring 118 
within the last 5% of the transcript and within exons flanked by non-canonical splice 119 
sites, splice site mutations at small (<15 bp) introns, at non-canonical splice sites, and 120 
where the purported pLoF allele is observed across primates. Common pLoF alleles are 121 
less likely to exert strong functional effects as they are less constrained by purifying 122 
selection; thus, we define pLoF mutations in the rest of the manuscript as variants with a 123 
minor allele frequency (MAF) of < 1% and passing the aforementioned bioinformatic 124 
filters. Applying these criteria, we generated a set of 49,138 pLoF mutations across 125 
13,074 autosomal genes.10 The site-frequency spectrum for these pLoF mutations 126 
revealed that the majority was seen only in one or a few individuals (Supplementary 127 
Figure 2).  128 
 Across all 10,503 PROMIS participants, both copies of 1,317 distinct genes were 129 
predicted to be inactivated due to pLoF mutations. A full listing of all 1,317 genes 130 
knocked out, the number of knockout participants for each gene, and the specific pLoF 131 
mutation(s) are provided in Supplementary Table 1. 891 (67.7 %) of the genes were 132 
knocked out only in one participant (Fig. 1a). Nearly 1 in 5 sequenced participants (1,843 133 
individuals, 17.5 %) had at least one gene knocked by a homozygous pLoF mutation. 134 
1,504 of these 1,843 individuals (81.6 %) were homozygous pLoF carriers for just one 135 
gene, but a minority of participants were knockouts for more than one gene and one 136 
participant had six genes with homozygous pLoF genotypes.  137 
We compared the coefficient of inbreeding (F coefficient) in PROMIS 138 
participants with that of 15,249 individuals from outbred populations of European or 139 
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African American ancestry. The F coefficient estimates the excess homozygosity 140 
compared with an estimated outbred ancestor. PROMIS participants had a 4-fold higher 141 
median inbreeding coefficient compared to outbred populations (0.016 v 0.0041; P < 2 x 142 
10-16) (Fig. 1b). Additionally, those in PROMIS who reported that their parents were 143 
closely related had even higher median inbreeding coefficients than those who did not 144 
(0.023 v 0.013; P < 2 x 10-16). The F inbreeding coefficient was correlated with the 145 
number of homozygous pLoF genes present in each individual. (Spearman r = 0.31; P = 5 146 
x 10-231) (Fig. 1c). When restricted to individuals with high levels of inbreeding (F 147 
inbreeding coefficient > 6.25%, the expected degree of autozygosity from a first-cousin 148 
union), 721 of 1,585 individuals (45%) were homozygous for at least one pLoF mutation. 149 
We tested the hypothesis that genes observed in the homozygous pLoF state in 150 
PROMIS participants are under less evolutionary constraint. We calculated the 151 
probability of being LoF intolerant (at >90% threshold) for each gene (see Methods) 11,12 152 
and compared this to 1,317 randomly selected genes. The observed 1,317 homozygous 153 
pLoF genes were less likely to be classified as highly constrained (odds ratio 0.14; 95% 154 
CI 0.12, 0.16; P < 1 x 10-10). Additionally, the 1,317 homozygous pLoF genes are 155 
substantially depleted of genes described to be essential for survival and proliferation in 156 
four human cancer cell lines (12 of 870 essential genes observed, 1.4%).13 157 
A number of genes previously predicted to be required for viability in humans 158 
were observed in the homozygous pLoF state in humans (Supplementary Table 2). For 159 
example, 40 of the 1,317 genes have been associated with embryonic or perinatal 160 
lethality as homozygous pLoF in mice.14 Furthermore, 56 genes predicted to be essential 161 
using mouse/human conservation data15 are tolerated as homozygous pLoF in Pakistani 162 
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adults. In fact, 9 genes are in both datasets and are also modeled as LoF intolerant.12 One 163 
such gene, EP400 (also known as p400), influences cell cycle regulation via chromatin 164 
remodeling16 and is critical for maintaining the identity of murine embryonic stem cells17 165 
but we observe an adult human homozygous for disruption of a canonical splice site 166 
(intron 3 of 52; c.1435+1G>A) in EP400. Conversely, we observed 90 genes where the 167 
heterozygous pLoF genotype is of appreciable frequency but the homozygous pLoF 168 
genotype is depleted (at P value threshold < 0.05) (Supplementary Table 3). 169 
We compared our results to three recent reports where homozygous pLoF genes 170 
have been catalogued: in Pakistanis living in Britain, in Icelanders, and in the Exome 171 
Aggregation Consortium (ExAC). 3,223 Pakistanis living in Britain with a high degree of 172 
parental relatedness (mean 5.62% autozygosity) were sequenced to find 781 homozygous 173 
pLoF genes.18 The sequencing of 2,636 Icelanders and subsequent imputation into 174 
104,220 chip-genotyped Icelanders yielded 1,171 genes in the homozygous pLoF state.3  175 
Analysis of 52,451 multi-ethnic participants from ExAC (i.e., those not overlapping with 176 
current PROMIS study) found 877 genes to be knocked out.19 Here, we identify a total of 177 
734 unique genes in the homozygous pLoF state that were not observed in the other three 178 
studies (Supplementary Figure 3).  179 
Intersection of the four sets of genes from these studies revealed only 25 common 180 
to all four studies. For example, at phosphodiesteriase 11A (encoded by PDE11A), 181 
different mutations across the four populations lead to homozygous pLoF state 182 
(PROMIS: c.2424-1G>G, p.Cys554ValfsTer14, p.Arg307Ter; ExAC Latino: 183 
p.Arg307Ter; ExAC non-Finnish European: p.Cys554ValfsTer14, p.Arg307Ter; 184 
Icelanders: p.Arg7ThrfsTer30, p.Arg307Ter; British Pakistani: p.Arg57Ter). The Pde11a-185 
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/- mouse shows behavioral phenotypes and PDE11A is implicated in depression and 186 
schizophrenia in humans.20 Whether humans lacking PDE11A also display 187 
neuropsychiatric phenotypes remains to be determined. 188 
In order to understand the phenotypic consequences of complete disruption of the 189 
1,317 pLoF genes identified in the PROMIS study, we applied three approaches. First, 190 
for 426 genes where two or more participants were homozygous pLoF, we conducted an 191 
association screen against a panel of 201 phenotypic traits (Supplementary Table 4). 192 
Second, in blood samples from each of 84 participants, we measured 1,310 protein 193 
biomarkers using a new, multiplexed, aptamer-based proteomics assay. Third, at a single 194 
gene, apolipoprotein C-III (encoded by APOC3), we recalled participants based on 195 
genotype (three classes: ‘wild-type’, heterozygous pLoF, and homozygous pLoF) and 196 
performed provocative physiologic testing. 197 
At 426 genes where two or more participants were homozygous pLoF, we 198 
performed association analyses to determine whether homozygous pLoF mutation status 199 
was associated with variation in any of 201 traits. For quantitative traits, we compared 200 
mean trait values in homozygous pLoF carriers with non-carriers. For dichotomous traits, 201 
we performed logistic regression with trait status as the outcome variable and 202 
homozygous pLoF carrier status as the predictor variable. Details of covariate 203 
adjustments are presented in the Methods. Across quantitative and dichotomous traits, 204 
this resulted in the analysis of 18,959 gene-trait pairs and thus, we set Bonferroni-205 
adjusted significance threshold at P = 3 x 10-6.  206 
 The quantile-quantile plot of expected versus observed association results shows 207 
an excess of highly significant results without systematic inflation (Supplementary 208 
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Figure 4). Association results surpassed the Bonferroni significance threshold for 26 209 
gene-trait pairs (Supplementary Table 5). Below, we highlight seven results: PLA2G7, 210 
CYP2F1, TREH, A3GALT2, NRG4, SLC9A3R1, and APOC3.  211 
  Lipoprotein-associated phospholipase A2 (Lp-PLA2, encoded by PLA2G7) 212 
hydrolyzes phospholipids to generate lysophosphatidylcholine and oxidized nonesterified 213 
fatty acids. In observational epidemiologic studies, higher soluble Lp-PLA2 enzymatic 214 
activity has been correlated with increased risk for coronary heart disease; small molecule 215 
inhibitors of Lp-PLA2 have been developed for the treatment of coronary heart disease.21 216 
In PROMIS, we identified participants who are naturally deficient in the Lp-PLA2 217 
enzyme. Two participants are homozygous for a splice-site mutation, PLA2G7 218 
c.663+1G>A, and 106 are heterozygous for this same mutation. We observed a dose-219 
dependent response relationship between genotype and enzymatic activity: when 220 
compared with non-carriers, c.663+1G>A homozygotes have markedly lower Lp-PLA2 221 
enzymatic activity (-245 nmol/ml/min, P = 2 x 10-7) whereas the 106 heterozygotes had 222 
an intermediate effect (-120 nmol/ml/min, P = 2 x 10-77) (Fig. 2a-b). If Lp-PLA2 plays a 223 
causal role for coronary heart disease, one might expect those naturally deficient for this 224 
enzyme to have reduced risk for coronary heart disease. We tested the association of 225 
PLA2G7 c.663+1G>A with myocardial infarction across all participants and found that 226 
carriers of the pLoF allele did not have reduced risk (OR 0.97; 95% CI, 0.70 – 1.34; P = 227 
0.87) (Fig. 2c). In contrast, at two positive control genes, we replicated prior observations 228 
(Supplementary Table 6); at LDLR, heterozygous pLoF mutations increased MI risk 20-229 
fold and, at PCSK9, heterozygous pLoF mutations reduced risk by 78%. Of note, in two 230 
recent randomized controlled trials, pharmacologic Lp-PLA2 inhibition failed to reduce 231 
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risk for coronary heart disease,22,23 a result that might have been anticipated by this 232 
genetic analysis.24 233 
Cytochrome P450 2F1 (encoded by CYP2F1) is primarily expressed in the lung 234 
and metabolizes pulmonary-selective toxins, such as cigarette smoke, and thus, 235 
modulates the expression of environment-associated pulmonary diseases.25 At CYP2F1, 236 
we identified two participants homozygous for a splice-site mutation, c.1295-2A>G. 237 
When compared with non-carriers, c.1295-2A>G homozygotes displayed higher soluble 238 
interleukin 8 concentrations (3.7-fold increase, P = 2 x 10-6) (Supplementary Figure 5). 239 
CYP2F1 c.1295-2A>G heterozygosity had a more modest effect (2.4-fold increase, P = 2 240 
x 10-4). Interleukin 8 induces migration of neutrophils in airways and is a mediator of 241 
acute pulmonary inflammation and chronic obstructive pulmonary disease (COPD).26,27 242 
However, neither carrier reports a personal or family history of obstructive pulmonary 243 
disease; further studies of these participants are required to assess the roles of CYP2F1 244 
and interleukin 8 on pulmonary physiology. 245 
 Trehalase (encoded by TREH) is an intestinal enzyme that splits the naturally-246 
found unabsorbed disaccharide, trehalose, into two glucose molecules.28 Trehalase 247 
deficiency, an autosomal recessive trait, leads to abdominal pain, distention, and 248 
flatulence after trehalose ingestion. We identified six participants homozygous for a 249 
deletion of a splice acceptor site (c.90-250 
9_106delTCTCTGCAGTGAGATTTACTGCCACG) in exon 2. Homozygotes, unlike 251 
heterozygotes or non-carriers, had lower concentrations of several apolipoprotein B-252 
containing lipoprotein subfractions (Supplementary Table 5) (Supplementary Figure 253 
6). 254 
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 Alpha-1,3-galactosyltransferase 2 (encoded by A3GALT2) catalyzes the formation 255 
of the Gal-α1-3Galβ1-4GlcNAc-R (α-gal) epitope; the biological role of this enzyme in 256 
humans is uncertain.29 At A3GALT2, we identified two participants homozygous for a 257 
frameshift mutation, p.Thr106SerfsTer4. Compared with non-carriers, p.Thr106SerfsTer4 258 
homozygotes both had dramatically reduced concentrations of fasting C-peptide (-97.4%; 259 
P = 6 x 10-12) and insulin (-92.3%; P = 1 x 10-4). Such an association was only observed 260 
in the homozygous state (Supplementary Figure 7). A3galt2-/- mice and pigs have 261 
recently been shown to have glucose intolerance.30,31  262 
 To understand if the identification of only a single homozygote may still be 263 
informative, we performed a complementary analysis, focusing on those with the most 264 
extreme standard Z scores (|Z score| > 5) and requiring that there be evidence for 265 
association in heterozygotes as well (see Methods). This procedure highlighted neureglin 266 
4 (NRG4), a member of the epidermal growth factor family extracellular ligands which is 267 
highly expressed in brown fat, particularly during adipocyte differentiation.32,33 At NRG4, 268 
we identified a single participant homozygous for a frameshift mutation, 269 
p.Ile75AsnfsTer23, who had nearly absent fasting insulin C-peptide concentrations (-99.3 270 
%; P = 1 x 10-10). When compared with non-carriers, heterozygotes for NRG4 271 
p.Ile75AsnfsTer23 (n = 8) displayed 48.3 % reduction in insulin C-peptide (P = 1 x 10-2).  272 
Mice deleted for Nrg4 have recently been shown to have glucose intolerance.33 The 273 
single NRG4 pLoF homozygote participant did not have diabetes nor elevated fasting 274 
glucose. Heterozygosity for a NRG4 pLoF mutation (n=26) was also not associated with 275 
diabetes or fasting glucose. More detailed phenotyping will be required to definitively 276 
assess any relationship of NRG4 deficiency in humans with glucose intolerance. 277 
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 To further dissect the consequences of a subset of homozygous pLoF genes, we 278 
measured 1,310 protein biomarkers in 84 participants through a new, multiplexed, 279 
proteomic assay (SOMAscan). Among the 84 participants, there were nine genes with at 280 
least two pLoF homozygotes and we associated these genotypes across 1,310 protein 281 
biomarkers and observed a number of associations (Supplementary Table 7). We 282 
highlight two PROMIS participants who are homozygous pLoF at SLC9A3R1; these 283 
participants have increased circulating concentrations of several proteins involved in 284 
parathyroid hormone or osteoclast signaling including calcium / calmodulin-dependent 285 
protein kinase II (CAMK2) alpha, beta, and delta subunits, cAMP-regulated 286 
phosphoprotein 19, and signal transducer and activator of transcription (STAT) 1, 3, and 287 
6 (Supplementary Table 7). SLC9A3R1 (aka NHERF1) encodes a Na+/H+ exchanger 288 
regulatory cofactor that interacts with and regulates the parathyroid hormone receptor; 289 
Nherf1-/- mice display hyperphosphaturia and disrupted protein kinase A-dependent 290 
cAMP-mediated phosphorylation.34,35 Humans carrying rare missense mutations in 291 
SLC9A3R1 have nephrolithiasis, osteoporosis, and hypophosphatemia.36 292 
Apolipoprotein C-III (apoC-III, encoded by APOC3) is a major protein 293 
component of chylomicrons, very low-density lipoprotein cholesterol, and high-density 294 
lipoprotein cholesterol.37 We and others recently reported that APOC3 pLoF mutations in 295 
heterozygous form lower plasma triglycerides and reduce risk for coronary heart 296 
disease5,6,38; there is now substantial interest in APOC3 as a therapeutic target.39-41 In 297 
published studies, no APOC3 pLoF homozygotes have been identified despite study of 298 
nearly 200,000 participants from the U.S. and Europe, raising concerns that complete 299 
APOC3 deficiency may be harmful. However, in our study of ~10,000 Pakistanis, we 300 
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identified four participants homozygous for APOC3 p.Arg19Ter. When compared with 301 
non-carriers, p.Arg19Ter homozygotes displayed near-absent plasma apoC-III protein (-302 
88.9 %, P = 5 x 10-23), lower plasma triglyceride concentrations (-59.6 %, P = 7 x 10-4), 303 
higher high-density lipoprotein (HDL) cholesterol  (+26.9 mg/dL, P = 3 x 10-8); and 304 
similar levels of low-density lipoprotein (LDL) cholesterol (P = 0.14) (Fig. 3a-d).  305 
ApoC-III functions as a brake on the metabolism of dietary fat and thus, the 306 
complete lack of this protein should promote handling of ingested fat. We re-contacted 307 
one homozygous pLoF proband, his wife, and 27 of his first-degree relatives for 308 
genotyping and physiologic investigation. We found that the proband’s wife, a first 309 
cousin, was also a pLoF homozygote, leading to all nine children being obligate 310 
homozygotes (Fig. 3e). In this family, we challenged pLoF homozygotes (APOC3-/- ; n = 311 
6) and non-carriers (APOC3+/+ ; n = 7) with a 50 g/m2 oral fat load followed by serial 312 
blood testing for six hours. APOC3 p.Arg19Ter homozygotes had significantly lower 313 
post-prandial triglyceride excursions (triglycerides area under the curve 468.3 mg/dL*6 314 
hours vs 1267.7 mg/dL*6 hours; P = 1 x 10-4) (Fig. 3f). These data show that complete 315 
lack of apoC-III markedly improves clearance of plasma triglycerides after a fatty meal 316 
and are consistent with and extend an earlier report of diminished post-prandial lipemia 317 
in APOC3 pLoF heterozygotes.38  318 
Targeted gene disruption in model organisms followed by phenotypic analysis has 319 
been a fruitful approach to understand gene function42; here, we extend this concept to 320 
the human organism, leveraging naturally-occurring pLoF mutations, consanguinity, and 321 
biochemical phenotyping. These results permit several conclusions. First, power to 322 
identify human knockouts is improved with the study of multiple populations and 323 
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particularly those with high degrees of consanguinity. Using the observed median 324 
inbreeding coefficient of sequenced participants and genotypes from the first 7,078 325 
sequenced Pakistanis, we estimate that the sequencing of 200,000 Pakistanis, may result 326 
in up to 8,754 genes (95% CI, 8,669-8,834) completely knocked out in at least one 327 
participant (Fig. 4).  328 
Second, a panel of phenotypes measured in a blood sample can yield hypotheses 329 
regarding phenotypic consequences of gene disruption as observed for PLA2G7, 330 
CYP2F1, TREH, A3GALT2, NRG4, SLC9A3R1, and APOC3. Finally, recall by genotype 331 
followed by provocative testing may provide physiologic insights. We used this approach 332 
to demonstrate that complete lack of apoC-III is tolerated and results in both lowered 333 
fasting triglyceride concentrations as well as substantially blunted post-prandial lipemia.  334 
Several limitations deserve mention. First and most importantly, any given 335 
mutation annotated as pLoF may not truly lead to loss of protein function. In addition to 336 
bioinformatics filtration, we manually curated all homozygous pLoF variants (n=1,580) 337 
to assess confidence in variant fidelity and predicted biochemical impact 338 
(Supplementary Table 1 and Supplementary Table 8). We found 56 variants with 339 
genotypes with a low number of supportive reads, 55 with poorly mapped reads 340 
(Supplementary Table 9), and an additional 66 where there were potential mechanisms 341 
of protein-truncation rescue (Supplementary Figure 8) or occurred within exons or 342 
splice sites where conservation was low. Thus, we found the majority of pLoF calls (1403 343 
out of 1580; 89%) to be free of mapping or annotation error. However, for any given 344 
pLoF, experimental validation will be required to prove loss of gene function (e.g., 345 
targeted assays such as RT-PCR of transcript and/or Western blot of protein to confirm 346 
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its absence). Second, statistical power for genotype-phenotype correlation is low if a gene 347 
is knocked-out in only 1 or 2 participants. However, this situation should improve with 348 
larger sample sizes (Supplementary Figure 9). Third, statistical power in the proteomics 349 
analysis may be low because of the limited number of samples assayed and the impact of 350 
non-genetic factors on plasma concentrations.43 Finally, our analysis was limited to 351 
available phenotypes and in only one instance did we recall participants for deeper 352 
phenotyping; rather, a standardized clinical phenotyping protocol is desirable for each 353 
participant where a gene is observed to be knocked out. 354 
To date, most human genetic studies have pursued a phenotype-first (“forward” 355 
genetics) approach, beginning with traits of interest followed by genetic mapping. It is 356 
now feasible to pursue a systematic genotype-first (“reverse” genetics) approach, starting 357 
with homozygous pLoF humans followed by methodical examination of a diverse set of 358 
traits.   359 
These observations set the stage for a ‘human knockout project,’ a systematic 360 
effort to understand the phenotypic consequences of complete disruption of every gene in 361 
the human genome. Key elements for a human knockout project include: 1) identification 362 
of populations where homozygous genotypes may be enriched18,44; 2) deep-coverage 363 
sequencing of the protein-coding regions of the genome3; 3) availability of a broad array 364 
biochemical as well as clinical phenotypes across the population; 4) ability to re-contact 365 
knockout humans as well as family members; 5) a thorough clinical evaluation in each 366 
participant where a gene is observed to be knocked out; and 6) hypothesis-driven 367 
provocative phenotyping in selected participants.   368 
 18
Methods 369 
General overview of the Pakistan Risk for Myocardial Infarction Study (PROMIS). 370 
The PROMIS study was designed to investigate determinants of cardiometabolic diseases 371 
in Pakistan. Since 2005, the study has enrolled close to 38,000 participants; the present 372 
investigation sequenced 10,503 participants selected as 4,793 cases with myocardial 373 
infarction and 5,710 controls free of myocardial infarction. Participants aged 30-80 years 374 
were enrolled from nine recruitment centers based in five major urban cities in Pakistan. 375 
Type 2 diabetes in the study was defined based on self-report or fasting glucose levels 376 
>125 mg/dL or HbA1c > 6.5 % or use of glucose lowering medications. The institutional 377 
review board at the Center for Non-Communicable Diseases (IRB: 00007048, 378 
IORG0005843, FWAS00014490) approved the study and all participants gave informed 379 
consent. 380 
 381 
Phenotype descriptions. 382 
Non-fasting blood samples (with the time since last meal recorded) were drawn and 383 
centrifuged within 45 minutes of venipuncture. Serum, plasma and whole blood samples 384 
were stored at -70°C within 45 minutes of venipuncture. All samples were transported on 385 
dry ice to the central laboratory at the Center for Non-Communicable Diseases (CNCD), 386 
Pakistan, where serum and plasma samples were aliquoted across 10 different storage 387 
vials. Samples were stored at -70°C for any subsequent laboratory analyses. All 388 
biochemical assays were conducted in automated auto-analyzers. At CNCD Pakistan, 389 
measurements for total-cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and 390 
creatinine were made in serum samples using enzymatic assays; whereas levels of HbA1c 391 
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were measured using a turbidemetric assay in whole-blood samples (Roche Diagnostics, 392 
USA). For further measurements, aliquots of serum and plasma samples were transported 393 
on dry ice to the Smilow Research Center, University of Pennsylvania, USA, where 394 
following biochemical assays were conducted: apolipoproteins (apoA-I, apoA-II, apoB, 395 
apoC-III, apoE) and non-esterified fatty acids were measured through 396 
immunoturbidometric assays using kits by Roche Diagnostics or Kamiya; lipoprotein (a) 397 
levels were determined through a turbidimetric assay using reagents and calibrators from 398 
Denka Seiken (Niigata, Japan); LpPLA2 mass and activity levels were determined using 399 
immunoassays manufactured by diaDexus (San Francisco, CA, USA); measurements for 400 
insulin, leptin and adiponectin were made using radio-immunoassays by LINCO (MO, 401 
USA); levels of adhesion molecules (ICAM-1, VCAM-1, P- and E-Selectin) were 402 
determined through enzymatic assays by R&D (Minneapolis, MN, USA); and 403 
measurements for C-reactive protein, alanine transaminase, aspartate transaminase, 404 
cystatin-C, ferritin, ceruloplasmin, thyroid stimulating hormone, alkaline phosphatase, 405 
sodium, potassium, choloride, phosphate, sex-harmone binding globulin were made using 406 
enzymatic assays manufactured by Abbott Diagnostics (NJ, USA).  Glomerular filtration 407 
rate (eGFR) was estimated from serum creatinine levels using the MDRD equation. 408 
ApoC-III levels were determined in an autoanalyzer using a commercially available 409 
ELISA by Sekisui Diagnostics (Lexington, USA). We also measured the following 52 410 
protein biomarkers by multiplex immunoassay using a customised panel on the Luminex 411 
100/200 instrument by RBM (Myriad Rules Based Medicine, Austin, TX, USA): fatty 412 
acid binding protein, granuloctye monocyte colony stimulating factor, granulocyte colony 413 
stimulating factor, interferon gamma, interleukin-1 beta, interleukin 1 receptor, 414 
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interleukin 2, interleukin 3, interleukin 4, interleukin 5, interleukin 6, interleukin 7, 415 
interleukin 8, interleukin 10, interleukin 18, interleukin p40, interleukin p70, interleukin 416 
15, interleukin 17, interleukin 23, macrophage inflammatory protein 1 alpha, macrophage 417 
inflammatory protein 1 beta, malondialdehyde-modified LDL, matrix metalloproteinase 418 
2, matrix metalloproteinase 3, matrix metalloproteinase 9, nerve growth factor beta, 419 
tumor necrosis factor alpha, tumor necrosis factor beta, brain-derived neurotrophic factor, 420 
CD40, CD40 ligand, eotaxin, factor VII, insulin-like growth factor 1, lecithin-type 421 
oxidized LDL receptor 1, monocyte chemoattractant protein 1, myeloperoxidase, N-422 
terminal prohormone of brain natriuretic peptide, neuronal cell adhesion molecule, 423 
pregnancy-associated plasma protein A, soluble receptor for advanced glycation end-424 
products, sortilin, stem cell factor, stromal cell-derived factor 1, thrombomodulin, S100 425 
calcium binding protein B, and vascular endothelial growth factor.  426 
 427 
Laboratory methods for array-based genotyping. 428 
As previously described, a genomewide association scan was performed using the 429 
Illumina 660 Quad array at the Wellcome Trust Sanger Institute (Hinxton, UK) and using 430 
the Illumina HumanOmniExpress at Cambridge Genome Services, UK.45 Initial quality 431 
control (QC) criteria included removal of participants or single nucleotide 432 
polymorphisms (SNPs) that had a missing rate >5%. SNPs with a MAF <1% and a P-433 
value of <10-7 for the Hardy-Weinberg equilibrium test were also excluded from the 434 
analyses. In PROMIS, further QC included removal of participants with discrepancy 435 
between their reported sex and genetic sex determined from the X chromosome. To 436 
identify sample duplications, unintentional use of related samples (cryptic relatedness) 437 
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and sample contamination (individuals who seem to be related to nearly everyone in the 438 
sample), identity-by-descent (IBD) analyses were conducted in PLINK.46 439 
 440 
Laboratory methods for exome sequencing. 441 
Exome sequencing. Exome sequencing was performed at the Broad Institute. 442 
Sequencing and exome capture methods have been previously described.47,48 A brief 443 
description of the methods is provided below. 444 
Receipt/quality control of sample DNA. Samples were shipped to the Biological 445 
Samples Platform laboratory at the Broad Institute of MIT and Harvard (Cambridge, MA, 446 
USA). DNA concentration was determined by PicoGreen (Invitrogen; Carlsbad, CA, 447 
USA) prior to storage in 2D-barcoded 0.75 ml Matrix tubes at  -20 oC in the SmaRTStore 448 
(RTS, Manchester, UK) automated sample handling system. Initial quality control (QC) 449 
on all samples involving sample quantification (PicoGreen), confirmation of high- 450 
molecular weight DNA and fingerprint genotyping and gender determination (Illumina 451 
iSelect; Illumina; San Diego, CA, USA). Samples were excluded if the total mass, 452 
concentration, integrity of DNA or quality of preliminary genotyping data was too low. 453 
Library construction. Library construction was performed as previously described49, 454 
with the following modifications: initial genomic DNA input into shearing was reduced 455 
from 3µg to 10-100ng in 50µL of solution. For adapter ligation, Illumina paired end 456 
adapters were replaced with palindromic forked adapters, purchased from Integrated 457 
DNA Technologies, with unique 8 base molecular barcode sequences included in the 458 
adapter sequence to facilitate downstream pooling. With the exception of the palindromic 459 
forked adapters, the reagents used for end repair, A-base addition, adapter ligation, and 460 
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library enrichment PCR were purchased from KAPA Biosciences (Wilmington, MA, 461 
USA) in 96-reaction kits. In addition, during the post-enrichment SPRI cleanup, elution 462 
volume was reduced to 20 µL to maximize library concentration, and a vortexing step 463 
was added to maximize the amount of template eluted.  464 
In-solution hybrid selection. 1,970 samples underwent in-solution hybrid selection as 465 
previously described49, with the following exception: prior to hybridization, two 466 
normalized libraries were pooled together, yielding the same total volume and 467 
concentration specified in the publication. 8,808 samples underwent hybridization and 468 
capture using the relevant components of Illumina's Rapid Capture Exome Kit and 469 
following the manufacturer’s suggested protocol, with the following exceptions: first, all 470 
libraries within a library construction plate were pooled prior to hybridization, and 471 
second, the Midi plate from Illumina’s Rapid Capture Exome Kit was replaced with a 472 
skirted PCR plate to facilitate automation. All hybridization and capture steps were 473 
automated on the Agilent Bravo liquid handling system. 474 
Preparation of libraries for cluster amplification and sequencing. Following post-475 
capture enrichment, libraries were quantified using quantitative PCR (KAPA Biosystems) 476 
with probes specific to the ends of the adapters. This assay was automated using 477 
Agilent’s Bravo liquid handling platform. Based on qPCR quantification, libraries were 478 
normalized to 2nM and pooled by equal volume using the Hamilton Starlet. Pools were 479 
then denatured using 0.1 N NaOH. Finally, denatured samples were diluted into strip 480 
tubes using the Hamilton Starlet. 481 
Cluster amplification and sequencing. Cluster amplification of denatured templates 482 
was performed according to the manufacturer’s protocol (Illumina) using HiSeq v3 483 
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cluster chemistry and HiSeq 2000 or 2500 flowcells. Flowcells were sequenced on HiSeq 484 
2000 or 2500 using v3 Sequencing-by-Synthesis chemistry, then analyzed using RTA 485 
v.1.12.4.2. Each pool of whole exome libraries was run on paired 76bp runs, with and 8 486 
base index sequencing read was performed to read molecular indices, across the number 487 
of lanes needed to meet coverage for all libraries in the pool. 488 
Read mapping and variant discovery. Samples were processed from real-time base-489 
calls (RTA v.1.12.4.2 software [Bustard], converted to qseq.txt files, and aligned to a 490 
human reference (hg19) using Burrows–Wheeler Aligner (BWA).50 Aligned reads 491 
duplicating the start position of another read were flagged as duplicates and not analysed. 492 
Data was processed using the Genome Analysis ToolKit (GATK v3).51-53 Reads were 493 
locally realigned around insertions-deletions (indels) and their base qualities were 494 
recalibrated. Variant calling was performed on both exomes and flanking 50 base pairs of 495 
intronic sequence across all samples using the HaplotypeCaller (HC) tool from the 496 
GATK to generate a gVCF. Joint genotyping was subsequently performed and ‘raw’ 497 
variant data for each sample was formatted (variant call format (VCF)). Single nucleotide 498 
polymorphisms (SNVs) and indel sites were initially filtered after variant calibration 499 
marked sites of low quality that were likely false positives.  500 
Data analysis QC. Fingerprint concordance between sequence data and fingerprint 501 
genotypes was evaluated. Variant calls were evaluated on both bulk and per- sample 502 
properties: novel and known variant counts, transition–transversion (TS–TV) ratio, 503 
heterozygous–homozygous non-reference ratio, and deletion/insertion ratio. Both bulk 504 
and sample metrics were compared to historical values for exome sequencing projects at 505 
the Broad Institute. No significant deviation of from historical values was noted. 506 
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 507 
Data processing and quality control of exome sequencing. 508 
Variant annotation. Variants were annotated using Variant Effect Predictor54 and the 509 
LOFTEE10 plugin to identify protein-truncating variants predicted to disrupt the 510 
respective gene’s function with “high confidence.” Each allele at polyallelic sites was 511 
separately annotated. 512 
Sample level quality control. We performed quality control of samples using the 513 
following steps. For quality control of samples, we used bi-allelic SNVs that passed the 514 
GATK VQSR filter and were on genomic regions targeted by both ICE and Agilent 515 
exome captures. We removed samples with discordance rate > 10% between genotypes 516 
from exome sequencing with genotypes from array-based genotyping and samples with 517 
sex mismatch between inbreeding coefficient on chromosome X and fingerprinting. We 518 
tested for sample contamination using the verifyBamID software, which examines the 519 
proportion of non-reference bases at reference sites, and excluded samples with high 520 
estimated contamination (FREEMIX scores > 0.2).55 After removing monozygotic twins 521 
or duplicate samples using the KING software56, we removed outlier samples with too 522 
many or too few SNVs (>17,000 or <12,000 total variants; >400 singletons; and >300 523 
doubletons). We removed those with extreme overall transition-to-transversion ratios 524 
(>3.8 or <3.3) and heterozygosity (heterozygote:non-reference homozygote ratio >6 or 525 
<2). Finally, we removed samples with high missingness (>0.05). 526 
Variant level quality control. Variant score quality recalibration was performed 527 
separately for SNVs and indels use the GATK VariantRecalibrator and 528 
ApplyRecalibration to filter out variants with lower accuracy scores. Additionally, we 529 
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removed sites with an excess of heterozygosity calls (InbreedingCoeff <-0.3). To further 530 
reduce the rate of inaccurate variant calls, we further filtered out SNVs with low average 531 
quality (quality per depth of coverage (QD) < 2) and a high degree of missingness (> 20 532 
%), and indels also with low average quality (quality per depth of coverage (QD) < 3) 533 
and a high degree of missingness (> 20 %).  534 
 535 
Laboratory methods for proteomics. 536 
Protein capture. For 91 participants, enriched for homozygous pLoF mutations, we 537 
measured 1,310 protein analytes in plasma using the SOMAscan assay (SomaLogic, 538 
Boulder, CO, USA). Protein-capture was performed using modified aptamer technology 539 
as previously described.57 Briefly, modified nucleotides, analogous to antibodies, on a 540 
custom DNA microarray recognize intact tertiary protein structures. After washing, 541 
complexes are released from beads by photocleavage of the linker with UV light and the 542 
resultant relative fluorescent unit is proportional to target protein. 543 
Quality control. Samples (n = 7) were excluded if they showed evidence of systematic 544 
inflation of association, or >5 % of traits in the top or bottom 1st percentile of the analytic 545 
distribution. 546 
 547 
Methods for manual curation of a subset of pLoF variants. 548 
Manual curation was performed collaboratively by three geneticists: 25 pLoF variant 549 
calls were reviewed independently by two reviewers and compared to ensure similar 550 
review criteria before the remainder was divided and separately assessed by each of the 551 
two reviewers separately. A third reviewer resolved discrepancies. Read and genotype 552 
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support was confirmed by review of reads in Integrative Genomics Viewer. We flagged 553 
pLoF variants for any of the following six reasons:  1) read-mapping flags; 2) genotyping 554 
flags; 3) presence of an additional polymorphism which rescues protein truncation; 4) 555 
presence of an additional polymorphism which rescues splice site; 5) if affecting a 556 
minority of transcripts; and 6) polymorphism occurs at exon or splice site with low 557 
conservation.  Criteria for these reasons are provided in Supplementary Table 8.  558 
 559 
Methods for inbreeding analyses. 560 
Array-derived runs of homozygosity. Analyses were conducted in PLINK46 using 561 
genome-wide association (GWAS) data in PROMIS and HapMap 3 populations. 562 
Segments of the genome that were at-least 1.5 Mb long, had a SNP density of 1 SNP per 563 
20 kb and had 25 consecutive homozygous SNPs (1 heterozygous and/or 5 missing SNPs 564 
were permitted within a segment) were defined to be in a homozygous state (or referred 565 
as “runs of homozygosity” (ROH)), as described previously.58 Homozygosity was 566 
expressed as the percentage of the autosomal genome found in a homozygous state, and 567 
was calculated by dividing the sum of ROH length within each individual by the total 568 
length of the autosome in PROMIS and HapMap 3 populations respectively. To 569 
investigate variability in homozygosity explained by parental consanguinity, the 570 
difference in R2 is reported for a linear regression model of homozygosity including and 571 
excluding parental consanguinity on top of age, sex and the first 10 principal components 572 
derived from the typed autosomal GWAS data.  573 
Sequencing-derived coefficient of inbreeding. We compared the coefficient of 574 
inbreeding distributions of 10,503 exome sequenced PROMIS participants with 15,248 575 
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participants (European ancestry = 12,849, and African ancestry = 2,399) who were 576 
exome sequenced at the Broad Institute (Cambridge, MA) from the Myocardial Infarction 577 
Genetics consortium.48 We extracted approximately 5,000 high-quality polymorphic 578 
SNVs in linkage equilibrium present on both target intervals that passed variant quality 579 
control metrics based on HapMap 3 data.59 Using PLINK, we estimated the coefficient of 580 
inbreeding separately within each ethnicity group.46 The coefficient of inbreeding was 581 
estimated as the observed degree of homozygosity compared with the anticipated 582 
homozygosity derived from an estimated common ancestor.60 The Wilcoxon-Mann-583 
Whitney test was used to test whether PROMIS participants had different median 584 
coefficients of inbreeding compared to other similarly sequenced outbred individuals and 585 
whether the median coefficient of inbreeding was different between PROMIS participants 586 
who reported parental relatedness versus not. A two-sided P of 0.05 was the pre-specified 587 
threshold for statistical significance. 588 
 589 
Methods for sequencing projection analysis. 590 
To compare the burden of unique completely inactivated genes in the PROMIS cohort 591 
with outbred cohorts of diverse ethnicities, we extracted the minor allele frequencies 592 
(maf) of "high confidence" loss-of-function mutations observed in the first 7,078 593 
sequenced PROMIS participants, and in European, African, and East Asian ancestry 594 
participants from the Exome Aggregation Consortium (ExAC r0.3; 595 
exac.broadinstitute.org). For each gene and for each ethnicity, the combined minor allele 596 
frequency (cmaf) of rare (maf < 0.1%) “high confidence” loss-of-function mutations was 597 
calculated. We then simulated the number of unique completely inactivated genes across 598 
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a range of sample sizes per ethnicity and PROMIS. The expected probability of observing 599 
complete inactivation (two pLoF copies in an individual) of a gene was calculated as 600 
(1 − ܨ) ∗ ݂ܿ݉ܽ ଶ +  ܨ ∗ ݂ܿ݉ܽ, which accounts for allozygous and autozygous, 601 
respectively, mechanisms for complete genie knockout. F, the inbreeding coefficient, is 602 
defined 603 
as ܨ = 1 − (݁ݔ݌݁ܿݐ݁݀ ℎ݁ݐ݁ݎ݋ݖݕ݃݋ݏ݅ݐݕ ݎܽݐ݁ / ݋ܾݏ݁ݎݒ݁݀ ℎ݁ݐ݁ݎ݋ݖݕ݃݋ݏ݅ݐݕ ݎܽݐ݁). For 604 
PROMIS, the median F inbreeding coefficient (0.016) was used for estimation. Down-605 
sampling within the observed sample size for both high-confidence pLoF mutations and 606 
synonymous variants did not deviate significantly from the expected trajectory 607 
(Supplementary Figure 11).  For a range of sample sizes (0-200,000), each gene was 608 
randomly sampled under a binomial distribution (ܺ ~ ܤ(݊, ݂ܿ݉ܽ)) and it was 609 
determined if the gene was successfully sampled at least once. To refine the estimated 610 
count of unique genes per sample size, each sampling was replicated ten times. 611 
 612 
Methods for constraint score analysis. 613 
We sought to determine whether the observed homozygous pLoF genes were under less 614 
evolutionary constraint by first obtaining constraint loss of function constraint scores 615 
derived from the Exome Aggregation Consortium (Lek M et al, in preparation).11,12 616 
Briefly, we used the number of observed and expected rare (MAF < 0.1%) loss of 617 
function variants per gene to determine to which of three classes it was likely to belong: 618 
pLoF (observed variation matches expectation), recessive (observed variation is ~50% 619 
expectation), or haploinsufficient (observed variation is <10% of expectation). The 620 
probability of being loss of function intolerant (pLI) of each transcript was defined as the 621 
 29
probability of that transcript falling into the haploinsufficient category. Transcripts with a 622 
pLI ≥ 0.9 are considered very likely to be loss of function intolerant; those with pLI ≤ 0.1 623 
are not likely to be loss of function intolerant. A list of 1,317 genes were randomly 624 
sampled from a list of sequenced genes 1,000 times and the proportion of loss of function 625 
intolerant genes compared to the proportion of the observed homozygous pLoF genes 626 
was compared using the chi square test. The likelihood that the distribution of the test 627 
statistics deviated from the pLoF was ascertained. 628 
 629 
Additionally, we sought to determine whether there were genes with appreciate pLoF 630 
allele frequencies yet relative depletion of homozygous pLoF genotypes. We computed 631 
estimated genotype frequencies based on Hardy-Weinberg equilibrium and the F 632 
inbreeding coefficient and compared the frequencies to the observed genotype counts 633 
with the chi square goodness-of-fit test. A nominal P < 0.05 is used to demonstrate at 634 
least nominal association. 635 
 636 
Methods for rare variant association analysis. 637 
Recessive model association discovery. We sought to determine whether complete loss-638 
of-function of a gene was associated with a dense array of phenotypes. We extracted a list 639 
of individuals per gene who were homozygous for a high confidence pLoF allele that was 640 
rare (minor allele frequency < 1 %) in the cohort. From a list of 1,317 genes where there 641 
was at least one participant homozygous pLoF and a list of 201 traits, we initially 642 
considered 264,717 gene-trait pairings. To reduce the likelihood of false positives, we 643 
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only considered gene-trait pairs where there were at least two homozygous pLoF alleles 644 
per gene phenotyped for a given trait yielding 18,959 gene-trait pairs for analysis. 645 
For all analyses, we constructed generalized linear models to test whether complete loss 646 
of function versus non-carriers was associated with trait variation. A logit link was used 647 
for binomial outcomes. Right-skewed continuous traits were natural log transformed. 648 
Age, sex, and myocardial infarction status were used as covariates in all analyses. We 649 
extracted principal components of ancestry using EIGENSTRAT to control for 650 
population stratification in all analyses.61 For lipoprotein-related traits, the use of lipid-651 
lowering therapy was used as a covariate. For glycemic biomarkers, only non-diabetics 652 
were used in the analysis. The P threshold for statistical significance was 0.05 / 18,959 = 653 
3 x 10-6. 654 
Heterozygote association replication. We hypothesized that some of the associations 655 
for homozygous pLoF alleles will display a more modest effect for heterozygous pLoF 656 
alleles. Thus, the aforementioned analyses were performed comparing heterozygous 657 
pLoF carriers to non-carriers for the 26 homozygous pLoF-trait associations that 658 
surpassed prespecified statistical significance. A P of 0.05 / 26 = 0.002 was set for 659 
statistical significance for these restricted analyses. 660 
Association for single genic homozygotes. We performed an exploratory analysis of 661 
gene-trait pairs where there was only one phenotyped homozygous pLoF. We performed 662 
the above association analyses for genes where there was only one homozygous pLoF 663 
phenotyped for a given trait and we focused on those with the most extreme standard Z 664 
score statistics (|Z score| > 5) from the primary association analysis and required that 665 
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there to also be nominal evidence for association (P < 0.05) in heterozygotes as well to 666 
maximize confidence in an observed single homozygous pLoF-trait association. 667 
Recessive model association discovery for proteomics. Among the 84 participants with 668 
proteomic analyses of 1,310 protein analytes, 9 genes were observed in the homozygous 669 
pLoF state at least twice. We log transformed each analyte and associated with 670 
homozygous pLoF genotype status, adjusting for proteomic plate, age, sex, myocardial 671 
infarction status, and principal components. Gene-analyte associations were considered 672 
significant if P values were less than 0.05 / (1,310 x 9) = 4.3 x 10-6. 673 
 674 
Methods for recruitment and phenotyping of an APOC3 p.Arg19Ter proband and 675 
relatives. 676 
Methods for Sanger sequencing. We collected blood samples from a total of 28 677 
subjects, including one of the four APOC3 p.Arg19Ter homozygous participants along 678 
with 27 of his family and community members for DNA extraction and separated into 679 
plasma for lipid and apolipoprotein measurements. All subjects were consented prior to 680 
initiation of the studies (IRB: 00007048 at the Center for Non-Communicable Diseases, 681 
Paksitan). DNA was isolated from whole blood using a reference phenol-chloroform 682 
protocol.62 Genotypes for the p.Arg19Ter variant were determined in all 28 participants 683 
by Sanger sequencing. A 685 bp region of the APOC3 gene including the base position 684 
for this variant was amplified by PCR (Expand HF PCR Kit, Roche) using the following 685 
primer sequences: Forward primer CTCCTTCTGGCAGACCCAGCTAAGG, Reverse 686 
primer CCTAGGACTGCTCCGGGGAGAAAG. PCR products were purified with Exo-687 
SAP-IT (Affymetrix) and sequenced via Sanger sequencing using the same primers. 688 
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Oral fat tolerance test. Six non-carriers and seven homozygotes also participated in an 689 
oral fat tolerance test. Participants fasted overnight and then blood was drawn for 690 
measurement of baseline fasted lipids. Following this, participants were administered an 691 
oral load of heavy cream (50 g fat per square meter of body surface area as calculated by 692 
the method of Mosteller63). Participants consumed this oral load within a time span of 20 693 
minutes and afterwards consumed 200 mL of water. Blood was drawn at 2, 4, and 6 hours 694 
after oral fat consumption as done previously.38,64 All lipid and apolipoprotein 695 
measurements from these plasma samples were determined by immunoturbidimetric 696 
assays on an ACE Axcel Chemistry analyzer (Alfa Wasserman). A comparisons of area-697 
under-the curve triglycerides was performed between APOC3 p.Arg19Ter homozygotes 698 
and non-carriers using a two independent sample Student’s t test; P < 0.05 was 699 
considered statistically significant.   700 
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Tables 701 
Table 1. Baseline characteristics of exome sequenced study participants. 702 
Characteristic Value 
(n = 10,503) 
  
Age (yrs) – mean (sd) 52.0 (9.0) 
Women – no. (%) 1,802 (17.2 %) 
Parents closely related – no. (%) 4,101 (39.0 %) 
Spouse closely related – no. (%) 4,182 (39.8 %) 
Ethnicity – no. (%)  
     Urdu 3,846 (36.6 %) 
     Punjabi 3,668 (34.9 %) 
     Sindhi 1,128 (10.7 %) 
     Pathan 589 (5.6 %) 
     Memon 141 (1.3 %) 
     Gujarati 109 (1.0 %) 
     Balochi 123 (1.2 %) 
     Other 891 (8.5 %) 
Hypertension – no. (%)* 4,744 (45.2 %) 
Hypercholesterolemia – no. (%)† 2,924 (27.8 %) 
Diabetes mellitus – no. (%)‡ 4,264 (40.6 %) 
Coronary heart disease – no. (%)§ 4,793 (45.6 %) 
Smoking – no. (%)|| 4,201 (40.0 %) 
 34
BMI (m/kg2) – mean (sd) 25.9 (4.2) 
*Hypertension defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure 703 
≥90 mmHg, or antihypertensive treatment. 704 
†Hypercholesterolemia defined as serum total cholesterol >240 mg/dL, lipid lowering 705 
therapy or self-report. 706 
‡Diabetes defined as fasting blood glucose ≥126 mg/dL, or HbA1c >6.5 %, oral 707 
hypoglycemics, insulin treatment, or self-report. 708 
§Coronary heart disease defined as acute myocardial infarction as determined by clinical 709 
symptoms with typical EKG findings or elevated serum troponin I. 710 
||Smoking defined as active current or prior tobacco smoking. 711 
  712 
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Figure Legends 713 
 714 
Fig 1. a, Most genes are observed in the homozygous pLoF state in only single 715 
individuals. b. The distribution of F inbreeding coefficient of PROMIS participants is 716 
compared to those of outbred samples of African (AFR) and European (EUR) ancestry. c, 717 
The burden of homozygous pLoF genes per individual is correlated with coefficient of 718 
inbreeding.  719 
 720 
Fig 2. a.-b. Carriage of a splice-site mutation, c.663+1G>A, in PLA2G7 leads to a dose-721 
dependent reduction of both lipoprotein-associated phospholipase A2 (Lp-PLA2) mass 722 
and activity, with homozygotes having no circulating Lp-PLA2. c. Despite substantial 723 
reductions of Lp-PLA2 activity, PLA2G7 c.663+1G>A heterozygotes and homozygotes 724 
have similar coronary heart disease risk when compared with non-carriers. 725 
 726 
Fig 3. a.-d. APOC3 pLoF genotype status, apolipoprotein C-III, triglycerides, HDL 727 
cholesterol and LDL cholesterol distributions among all sequenced participants. 728 
Apolipoprotein C-III concentration is displayed on a logarithmic base 10 scale. e. A 729 
proband with APOC3 pLoF homozygote genotype as well as several family members 730 
were recalled for provocative phenotyping. Surprisingly, the spouse of the proband was 731 
also a pLoF homozygote, leading to nine obligate homozygote children. Given the 732 
extensive first-degree unions, the pedigree is simplified for clarity. f. APOC3 p.Arg19Ter 733 
homozygotes and non-carriers within the same family were challenged with a 50 g/m2 fat 734 
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feeding. Homozygotes had lower baseline triglyceride concentrations and displayed 735 
marked blunting of post-prandial rise in plasma triglycerides. 736 
 737 
Fig 4. Number of unique homozygous pLoF genes anticipated with increasing sample 738 
sizes sequenced in PROMIS compared with similar African (AFR) and European (EUR) 739 
sample sizes. Estimates derived using observed allele frequencies and degree of 740 





Fig. 1. Homozygous pLoF burden in PROMIS is driven by excess autozygosity. 745 
  746 
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 747 
Fig. 2. Carriers of PLA2G7 splice mutation have diminished Lp-PLA2 mass (P = 6 x 748 
10-5) and activity (P = 2 x 10-7) but similar risk for coronary heart disease risk when 749 
compared to non-carriers (P = 0.87). 750 
  751 
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 752 
Fig 3. APOC3 pLoF homozygotes have diminished fasting triglycerides and blunted 753 
post-prandial lipemia.  754 
 40
 755 
Fig 4. Simulations anticipate many more homozygous pLoF genes in the PROMIS 756 
cohort.  757 
 41
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